JP2019108366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019108366A5 JP2019108366A5 JP2019038349A JP2019038349A JP2019108366A5 JP 2019108366 A5 JP2019108366 A5 JP 2019108366A5 JP 2019038349 A JP2019038349 A JP 2019038349A JP 2019038349 A JP2019038349 A JP 2019038349A JP 2019108366 A5 JP2019108366 A5 JP 2019108366A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- compound
- formula
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000002270 dispersing agent Substances 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 238000007922 dissolution test Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- ZFHQRKNHABBCOO-MONFIQOXSA-N (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide trihydrate Chemical compound O.O.O.C[C@@H]1[C@@H](C[C@@H](C(N1CC(F)(F)F)=O)NC(=O)C=1C=C2C(=NC1)C[C@]1(C2)C(NC2=NC=CC=C21)=O)C2=CC=CC=C2 ZFHQRKNHABBCOO-MONFIQOXSA-N 0.000 claims 1
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=CC=CC=C1 DDOOFTLHJSMHLN-ZQHRPCGSSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical group CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936019P | 2014-02-05 | 2014-02-05 | |
| US61/936,019 | 2014-02-05 | ||
| US201462087366P | 2014-12-04 | 2014-12-04 | |
| US62/087,366 | 2014-12-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Division JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019108366A JP2019108366A (ja) | 2019-07-04 |
| JP2019108366A5 true JP2019108366A5 (enExample) | 2019-11-21 |
| JP6666490B2 JP6666490B2 (ja) | 2020-03-13 |
Family
ID=53778348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Active JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
| JP2019038349A Active JP6666490B2 (ja) | 2014-02-05 | 2019-03-04 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Active JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10117836B2 (enExample) |
| EP (1) | EP3102564A4 (enExample) |
| JP (2) | JP6491669B2 (enExample) |
| KR (3) | KR102448369B1 (enExample) |
| CN (2) | CN112022818A (enExample) |
| AU (5) | AU2015214502B2 (enExample) |
| CA (1) | CA2937315A1 (enExample) |
| HK (1) | HK1232218A1 (enExample) |
| IL (1) | IL246828B (enExample) |
| MX (2) | MX383378B (enExample) |
| RU (2) | RU2019123406A (enExample) |
| SA (1) | SA516371613B1 (enExample) |
| WO (1) | WO2015119848A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI501968B (zh) * | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| CN112022818A (zh) | 2014-02-05 | 2020-12-04 | 默沙东公司 | Cgrp-活性化合物的片剂制剂 |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
| HUE064474T2 (hu) * | 2017-03-30 | 2024-03-28 | Merck Patent Gmbh | Gyógyászati kiszerelés |
| KR20200135465A (ko) * | 2018-03-25 | 2020-12-02 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Cgrp 관련 장애를 위한 리메게판트 |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| RU2755571C1 (ru) * | 2020-06-09 | 2021-09-17 | Сергей Геннадьевич Каплунов | Способ изготовления гравюры на металле |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| MX2023005846A (es) * | 2020-11-19 | 2023-06-02 | Pfizer Ireland Pharmaceuticals | Composiciones para la administracion mejorada de los inhibidores de cgrp. |
| TW202241447A (zh) * | 2021-02-02 | 2022-11-01 | 瑞士商愛杜西亞製藥有限公司 | (4-甲基-2-[1,2,3]三唑-2-基-苯基)-[(r)-3-(3-[1,2,3]三唑-2-基-苄基)-嗎啉-4-基]-甲酮之結晶形式 |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| ATE509019T1 (de) | 2003-03-14 | 2011-05-15 | Merck Sharp & Dohme | Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten |
| CA2518830A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| DE602005020656D1 (de) | 2004-09-13 | 2010-05-27 | Merck Sharp & Dohme | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| US7994325B2 (en) | 2005-03-14 | 2011-08-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| CN103735515A (zh) * | 2006-02-09 | 2014-04-23 | 默沙东公司 | Cetp抑制剂的聚合物制剂 |
| MX2008014353A (es) | 2006-05-09 | 2008-11-24 | Merck & Co Inc | Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos. |
| WO2008153849A1 (en) | 2007-06-05 | 2008-12-18 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| MX2010003849A (es) | 2007-10-18 | 2010-04-27 | Boehringer Ingelheim Int | Antagonistas de cgrp. |
| EP2225237A2 (de) | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| EP2249833B1 (en) * | 2008-02-05 | 2012-10-17 | Merck Sharp & Dohme Corp. | Prodrugs of cgrp receptor antagonist |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| PE20091778A1 (es) | 2008-04-15 | 2009-11-13 | Schering Corp | Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden |
| EP2413930A4 (en) * | 2009-03-31 | 2012-09-26 | Ligand Pharm Inc | ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY |
| JP5449540B2 (ja) | 2009-06-05 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US8883807B2 (en) | 2010-11-12 | 2014-11-11 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane CGRP receptor antagonists |
| TWI501968B (zh) * | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US8895572B2 (en) | 2010-12-22 | 2014-11-25 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide CGRP receptor antagonists |
| US9067941B2 (en) | 2010-12-22 | 2015-06-30 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide CGRP receptor antagonists |
| CN103491964A (zh) * | 2011-03-08 | 2014-01-01 | 扎里卡斯药品有限公司 | 固体分散体制剂及其使用方法 |
| EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| CN103998461B (zh) | 2011-09-08 | 2018-02-02 | 科德克希思公司 | 用于合成取代的内酰胺的生物催化剂和方法 |
| AU2012322039C1 (en) | 2011-10-14 | 2021-04-29 | Array Biopharma Inc. | Solid dispersions of a Erb2 (HER2) inhibitor |
| EP3680240A1 (en) | 2012-03-14 | 2020-07-15 | Merck Sharp & Dohme Corp. | Asymmetric phase transfer catalysis |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| US9833488B2 (en) | 2012-04-25 | 2017-12-05 | Centric Research Institute | Sensitization composition and method of use |
| WO2013169567A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| US9227972B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam CGRP receptor antagonists |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| WO2013169563A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
| ES2769879T3 (es) | 2013-03-15 | 2020-06-29 | Tonix Pharma Holdings Ltd | Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol |
| CN105531275B (zh) | 2013-09-16 | 2020-12-18 | 默沙东公司 | 用于cgrp受体拮抗剂的制剂 |
| CN112022818A (zh) | 2014-02-05 | 2020-12-04 | 默沙东公司 | Cgrp-活性化合物的片剂制剂 |
| EP3102188A4 (en) | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20170189443A1 (en) | 2014-02-24 | 2017-07-06 | C. Lowell Parsons | Compositions and methods for treatment of diseases and conditions employing oral administration of sodium pentosan polysulfate and other pentosan polysulfate salts |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| US10022353B2 (en) | 2015-01-23 | 2018-07-17 | Grünenthal GmbH | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
| JP2018532728A (ja) | 2015-09-24 | 2018-11-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | （持続性）外傷後頭痛の予防、治療および低減 |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| RU2770066C2 (ru) | 2017-03-02 | 2022-04-14 | Бет Изрейэл Диконисс Медикал Сентер, Инк. | Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| CA3133912A1 (en) | 2019-04-18 | 2020-10-22 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| US20220340650A1 (en) | 2019-09-25 | 2022-10-27 | Abnijeet JAKATE | Combination therapy with cgrp antagonists |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
-
2015
- 2015-01-30 CN CN202010812438.5A patent/CN112022818A/zh active Pending
- 2015-01-30 KR KR1020167024025A patent/KR102448369B1/ko active Active
- 2015-01-30 HK HK17105813.5A patent/HK1232218A1/zh unknown
- 2015-01-30 WO PCT/US2015/013672 patent/WO2015119848A1/en not_active Ceased
- 2015-01-30 US US15/115,026 patent/US10117836B2/en active Active
- 2015-01-30 KR KR1020227032939A patent/KR20220136460A/ko not_active Ceased
- 2015-01-30 JP JP2016548023A patent/JP6491669B2/ja active Active
- 2015-01-30 AU AU2015214502A patent/AU2015214502B2/en active Active
- 2015-01-30 MX MX2016010169A patent/MX383378B/es unknown
- 2015-01-30 RU RU2019123406A patent/RU2019123406A/ru unknown
- 2015-01-30 CN CN201580006288.6A patent/CN105960397B/zh active Active
- 2015-01-30 RU RU2016135536A patent/RU2696578C1/ru active
- 2015-01-30 CA CA2937315A patent/CA2937315A1/en active Pending
- 2015-01-30 KR KR1020237022803A patent/KR20230107902A/ko not_active Ceased
- 2015-01-30 EP EP15746768.9A patent/EP3102564A4/en active Pending
-
2016
- 2016-07-18 IL IL246828A patent/IL246828B/en active IP Right Grant
- 2016-08-04 MX MX2021006790A patent/MX2021006790A/es unknown
- 2016-08-04 SA SA516371613A patent/SA516371613B1/ar unknown
-
2018
- 2018-11-02 US US16/178,641 patent/US20190209478A1/en not_active Abandoned
-
2019
- 2019-03-04 JP JP2019038349A patent/JP6666490B2/ja active Active
- 2019-09-06 AU AU2019226239A patent/AU2019226239B2/en active Active
-
2020
- 2020-12-03 US US17/110,398 patent/US11925709B2/en active Active
-
2021
- 2021-10-08 AU AU2021245229A patent/AU2021245229A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/137,925 patent/US20230248655A1/en not_active Abandoned
- 2023-10-30 AU AU2023258317A patent/AU2023258317A1/en not_active Abandoned
-
2025
- 2025-08-22 AU AU2025220825A patent/AU2025220825A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019108366A5 (enExample) | ||
| JP2784184B2 (ja) | スフェロイド | |
| CN1163223C (zh) | 肠内目标部位释放型制剂 | |
| CN113274355B (zh) | 利福昔明固体分散体 | |
| ES2337935T3 (es) | Comprimidos de accion retardada con hidromorfona. | |
| JPH09143073A (ja) | 持続性ニフエジピン製剤 | |
| TW200301139A (en) | Zero-order sustained release dosage forms and method of making same | |
| WO2010103544A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
| WO2006082523A2 (en) | Pharmaceutical sustained release composition of metformin | |
| CN107205950B (zh) | 金刚烷胺组合物的施用方法 | |
| TW201113050A (en) | 3-cyanoquinoline tablet formulations and uses thereof | |
| CN101854929A (zh) | 新型制剂 | |
| WO2018108157A1 (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| BR112015010271B1 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
| JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
| Aslam et al. | Techniques and polymers used to design Gastroretentive drug delivery systems–a review | |
| CN106511312A (zh) | 一种复方西地那非达泊西汀缓释胶囊及其制备方法 | |
| CN101011393B (zh) | 厄贝沙坦胃内滞留型缓释药物组合物 | |
| ES2899885T3 (es) | Nueva composición farmacéutica de liberación diferencial que contiene tres principios activos | |
| JP2025078766A (ja) | ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法 | |
| CN116059175B (zh) | 一种普瑞巴林胃漂浮缓释片及其制备方法 | |
| JPS61286330A (ja) | 経口徐放性製剤 | |
| JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
| CN107249569A (zh) | 一种包含含有盐酸坦索罗辛的缓释颗粒的口服药物制剂 |